We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · December 30, 2020

DOAC vs Low–Molecular Weight Heparin for Treatment of VTE in Cancer Patients

Thrombosis Research


Additional Info

Disclosure statements are available on the authors' profiles:

Thrombosis Research
Direct Oral Anticoagulant Versus Low-Molecular-Weight Heparin for Treatment of Venous Thromboembolism in Cancer Patients: An Updated Meta-Analysis of Randomized Controlled Trials
Thromb. Res. 2020 Oct 01;194(0)57-65, T Haykal, Y Zayed, S Deliwala, J Kerbage, A Ponnapalli, S Malladi, S Goranta, V Samji, S Adam

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading